Skip to main content
SpringerLink
Log in

RKIP inhibits gastric cancer cell survival and invasion by regulating the expression of HMGA2 and OPN

  • Research Article
  • Published:
Tumor Biology

Abstract

The objective of this study was to explore the mechanism via which Raf kinase inhibitor protein (RKIP) suppresses the invasion of gastric cancer cells and promote apoptosis, with an attempt to provide evidences for the application of RKIP in treating gastric cancer. The recombinant plasmid pcDNA3.1-RKIP or RKIP-shRNA was transfected into the gastric cancer cell line SGC-7901 using liposome. Then, the messenger RNA (mRNA) and protein expressions of RKIP, HMGA2, and OPN were detected using qPCR and Western blotting. The effects of HMGA2 on the proliferation, apoptosis, and invasion of SGC-7901 cells were detected using flow cytometry and Transwell assay. To further explore the regulatory effect of PKIP on the biological activities of HMGA2, we over-expressed or knock down RKIP and HMGA2 simultaneously and detected its effects on the proliferation, apoptosis, and invasion of SGC-7901 cells. As shown by qPCR and Western blotting, after over-expression of RKIP in SGC-7901 cells, the mRNA and protein expressions of RKIP significantly increased (P < 0.01), whereas the mRNA and protein expressions of HMGA2 and OPN significantly decreased (P < 0.01). In contrast, the transfection of RKIP-shRNA in the SGC-7901 cells resulted in opposite results. After over-expression of HMGA2 in SGC-7901 cells, the protein expression of HMGA2 significantly increased (P < 0.01); however, it significantly decreased after the transfection of HMGA2-shRNA (P < 0.01). As shown by Transwell assay and flow cytometry, After the over-expression of HMGA2 in SGC-7901 cells, the (G2 + S) phase fraction significantly increased (P < 0.01); also, the percentage of the apoptotic cells significantly declined (P < 0.05) and the number of invasive cells significantly increased (P < 0.05). However, the interference of the expression of HMGA2 resulted in opposite results. The simultaneous over-expression of RKIP and HMGA2 in SGC-7901 cells or the simultaneous interference of RKIP and HMGA2 showed no significant difference with the control group in terms of (G2 + S) phase fraction, percentage of apoptotic cells, and number of invasive cells (P > 0.05). In conclusion, RKIP can inhibit the survival and invasion of gastric cancer cells and promote apoptosis, possibly by regulating the expression of HMGA2 or OPN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, et al. Suppression of raf-1 kinase activity and map kinase signalling by rkip. Nature. 1999;401:173–7.

    Article  CAS  PubMed  Google Scholar 

  2. Zeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (rkip): a physiological regulator and future therapeutic target. Expert Opin Ther Targets. 2008;12:1275–87.

    Article  CAS  PubMed  Google Scholar 

  3. Lu TP, Tsai MH, Hsiao CK, Lai LC, Chuang EY. Expression and functions of semaphorins in cancer. Transl Cancer Res. 2012;1:74–87.

    Google Scholar 

  4. Khamis ZI, Iczkowski KA, Sang QX. Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents. Med Res Rev. 2012;32:1026–77.

    Article  CAS  PubMed  Google Scholar 

  5. Yamada Y. Molecular therapy for gastric cancer. Chin Clin Oncol. 2013;2:5.

    PubMed  Google Scholar 

  6. Wang YX, Wang DW, Zhu XM, Zhao F, Leung KC. Carbon coated superparamagnetic iron oxide nanoparticles for sentinel lymph nodes mapping. Quant Imaging Med Surg. 2012;2:53–6.

    PubMed  PubMed Central  Google Scholar 

  7. Kang B, Sun XH. Regulation of cancer stem cells by RING finger ubiquitin ligases. Stem Cell Investig. 2014;1:5.

    PubMed  PubMed Central  Google Scholar 

  8. Smith HS, Smith JM, Smith AR. An overview of nausea/vomiting in palliative medicine. Ann Palliat Med. 2012;1:103–14.

    PubMed  Google Scholar 

  9. Fedele M, Palmieri D, Fusco A. Hmga2: a pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol. 2010;326:19–24.

    Article  CAS  PubMed  Google Scholar 

  10. Wu J, Wei JJ. Hmga2 and high-grade serous ovarian carcinoma. J Mol Med. 2013;91:1155–65.

    Article  CAS  PubMed  Google Scholar 

  11. Cleynen I, Van de Ven WJ. The hmga proteins: a myriad of functions (review). Int J Oncol. 2008;32:289–305.

    CAS  PubMed  Google Scholar 

  12. Young AR, Narita M. Oncogenic hmga2: short or small? Genes Dev. 2007;21:1005–9.

    Article  CAS  PubMed  Google Scholar 

  13. Jonson L, Christiansen J, Hansen TV, Vikesa J, Yamamoto Y, Nielsen FC. Imp3 rnp safe houses prevent mirna-directed hmga2 mrna decay in cancer and development. Cell Rep. 2014;7:539–51.

    Article  PubMed  CAS  Google Scholar 

  14. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. Hmga2 maintains oncogenic ras-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol. 2009;174:854–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pagel CN, Wasgewatte Wijesinghe DK, Taghavi Esfandouni N, Mackie EJ. Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle. J Cell Commun Signal. 2013.

  16. Nagoshi S. Osteopontin: versatile modulator of liver diseases. Hepatol Res Off J Jpn Soc Hepatol. 2014;44:22–30.

    Article  CAS  Google Scholar 

  17. Gimba ER, Tilli TM. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 2013;331:11–7.

    Article  CAS  PubMed  Google Scholar 

  18. Cheng C, Gao S, Lei G. Association of osteopontin with osteoarthritis. Rheumatol Int. 2014.

  19. Chien CY, Tsai HT, Su LJ, Chuang HC, Shiu LY, Huang CC, et al. Aurora-a signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior. Oncotarget. 2014;5:2243–62.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Hunter GK. Role of osteopontin in modulation of hydroxyapatite formation. Calcif Tissue Int. 2013;93:348–54.

    Article  CAS  PubMed  Google Scholar 

  21. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst. 2003;95:878–89.

    Article  CAS  PubMed  Google Scholar 

  22. Xu YF, Yi Y, Qiu SJ, Gao Q, Li YW, Dai CX, et al. Pebp1 downregulation is associated to poor prognosis in hcc related to hepatitis b infection. J Hepatol. 2010;53:872–9.

    Article  CAS  PubMed  Google Scholar 

  23. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The role of b-raf mutations in melanoma and the induction of emt via dysregulation of the nf-kappab/snail/rkip/pten circuit. Genes Cancer. 2010;1:409–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Al-Mulla F, Hagan S, Al-Ali W, Jacob SP, Behbehani AI, Bitar MS, et al. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol. 2008;61:524–9.

    Article  CAS  PubMed  Google Scholar 

  25. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res. 2009;7:832–40.

    Article  CAS  PubMed  Google Scholar 

  26. Minn AJ, Bevilacqua E, Yun J, Rosner MR. Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle. 2012;11:2452–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bonavida B, Baritaki S. The novel role of yin yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated nf-kappab/snail/yy1/rkip/pten circuitry. Crit Rev Oncog. 2011;16:211–26.

    Article  PubMed  Google Scholar 

  28. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–61.

    PubMed  PubMed Central  Google Scholar 

  29. Wu Z, Fu C, Shi L, Ruan L, Lin D, Guo C. Structural basis for rkip binding with its substrate raf1 kinase. Biotechnol Lett. 2014;36:1869–74.

    Article  CAS  PubMed  Google Scholar 

  30. Bu Z, Zheng Z, Zhang L, Li Z, Sun Y, Dong B, et al. LGR5 is a promising biomarker for patients with stage I and II gastric cancer. Chin J Cancer Res. 2013;25:79–89.

    PubMed  PubMed Central  Google Scholar 

  31. McDaniel K, Correa R, Zhou T, Johnson C, Francis H, Glaser S, et al. Functional role of microvesicles in gastrointestinal malignancies. Ann Transl Med. 2013;1:4.

    PubMed  PubMed Central  Google Scholar 

  32. Franceschi F, Zuccala G, Roccarina D, Gasbarrini A. Clinical effects of helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol. 2014;11:234–42.

    Article  CAS  PubMed  Google Scholar 

  33. Bu Z, Ji J. A current view of gastric cancer in China. Transl Gastrointest Cancer. 2013;2(S1):1–4.

    Google Scholar 

  34. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol. 2011;137:1151–73.

    Article  PubMed  Google Scholar 

  35. Merchionne F, Iacopino P, Minoia C, Iacobazzi A, Rana A, Serratl S, et al. Targeted strategies in the treatment of primary gastric lymphomas: from rituximab to recent insights into potential new drugs. Curr Med Chem. 2014;21:1005–16.

    Article  CAS  PubMed  Google Scholar 

  36. Hardbower DM, Peek Jr RM, Wilson KT. At the bench: helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol. 2014;96:201–12.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 1846;2014:232–7.

    Google Scholar 

  38. Al-Mulla F, Bitar MS, Taqi Z, Yeung KC. Rkip: much more than raf kinase inhibitory protein. J Cell Physiol. 2013;228:1688–702.

    Article  CAS  PubMed  Google Scholar 

  39. Escara-Wilke J, Yeung K, Keller ET. Raf kinase inhibitor protein (rkip) in cancer. Cancer Metastasis Rev. 2012;31:615–20.

    Article  CAS  PubMed  Google Scholar 

  40. Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding J, et al. Microrna-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting hmga2. Int J Oncol. 2014;44:2050–8.

    Article  CAS  PubMed  Google Scholar 

  41. Xi YN, Xin XY, Ye HM. Effects of hmga2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells. Asian Pac J Trop Med. 2014;7:289–92.

    Article  CAS  PubMed  Google Scholar 

  42. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving lin28 and let-7. EMBO J. 2009;28:347–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Wei J, Li H, Wang S, Li T, Fan J, Liang X, et al. Let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating hmga2. Stem Cells Dev. 2014;23:1452–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Chen KJ, Hou Y, Wang K, Li J, Xia Y, Yang XY, et al. Reexpression of let-7 g microrna inhibits the proliferation and migration via k-ras/hmga2/snail axis in hepatocellular carcinoma. BioMed Res Int. 2014;2014:742417.

    PubMed  PubMed Central  Google Scholar 

  45. Sun M, Gomes S, Chen P, Frankenberger CA, Sankarasharma D, Chung CH, et al. Rkip and hmga2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene. 2013;33:3528–37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, General Hospital of Chinese People’s Liberation Army, No. 28, Fuxing Rd, Beijing, 100853, People’s Republic of China

    Hongyi Liu, Peng Li, Bing Li, Peng Sun, Jiajin Zhang, Baishi Wang & Baoqing Jia

Authors
  1. Hongyi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiajin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Baishi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Baoqing Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baoqing Jia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, H., Li, P., Li, B. et al. RKIP inhibits gastric cancer cell survival and invasion by regulating the expression of HMGA2 and OPN. Tumor Biol. 35, 11949–11958 (2014). https://doi.org/10.1007/s13277-014-2486-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2486-8

Keywords

Search

Navigation